$Carfilzomib-Dexamethasone vs Subcutaneous or Intravenous Bortezomib in Relapsed or Refractory Multiple Myeloma: Secondary Analysis of Phase 3 ENDEAVOR Study$

Carfilzomib-Dexamethasone vs Subcutaneous or Intravenous Bortezomib in Relapsed or Refractory Multiple Myeloma: Secondary Analysis of Phase 3 ENDEAVOR Study

10.1080/10428194.2017.1376743

Saved in:

Bibliographic Details
Main Authors:	Hartmut Goldschmidt, Philippe Moreau, Heinz Ludwig, Ruben Niesvizky, Wee Joo Chng, Douglas Joshua, Katja Weisel, Andrew Spencer, Robert Orlowski, Shibao Feng, Karim Iskander, Meletios A. Dimopoulos
Other Authors:	MEDICINE
Format:	Others
Published:	Taylor & Francis 2018
Online Access:	http://scholarbank.nus.edu.sg/handle/10635/143070
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

id	sg-nus-scholar.10635-143070
record_format	dspace
spelling	sg-nus-scholar.10635-1430702024-04-17T08:37:57Z Carfilzomib-Dexamethasone vs Subcutaneous or Intravenous Bortezomib in Relapsed or Refractory Multiple Myeloma: Secondary Analysis of Phase 3 ENDEAVOR Study Hartmut Goldschmidt Philippe Moreau Heinz Ludwig Ruben Niesvizky Wee Joo Chng Douglas Joshua Katja Weisel Andrew Spencer Robert Orlowski Shibao Feng Karim Iskander Meletios A. Dimopoulos MEDICINE 10.1080/10428194.2017.1376743 Leukemia & Lymphoma 59 6 1364-1374 2018-06-11T08:31:15Z 2018-06-11T08:31:15Z 2017-09-22 Others Hartmut Goldschmidt, Philippe Moreau, Heinz Ludwig, Ruben Niesvizky, Wee Joo Chng, Douglas Joshua, Katja Weisel, Andrew Spencer, Robert Orlowski, Shibao Feng, Karim Iskander, Meletios A. Dimopoulos (2017-09-22). Carfilzomib-Dexamethasone vs Subcutaneous or Intravenous Bortezomib in Relapsed or Refractory Multiple Myeloma: Secondary Analysis of Phase 3 ENDEAVOR Study. Leukemia & Lymphoma 59 (6) : 1364-1374. ScholarBank@NUS Repository. https://doi.org/10.1080/10428194.2017.1376743 1042-8194 http://scholarbank.nus.edu.sg/handle/10635/143070 Taylor & Francis
institution	National University of Singapore
building	NUS Library
continent	Asia
country	Singapore Singapore
content_provider	NUS Library
collection	ScholarBank@NUS
description	10.1080/10428194.2017.1376743
author2	MEDICINE
author_facet	MEDICINE Hartmut Goldschmidt Philippe Moreau Heinz Ludwig Ruben Niesvizky Wee Joo Chng Douglas Joshua Katja Weisel Andrew Spencer Robert Orlowski Shibao Feng Karim Iskander Meletios A. Dimopoulos
format	Others
author	Hartmut Goldschmidt Philippe Moreau Heinz Ludwig Ruben Niesvizky Wee Joo Chng Douglas Joshua Katja Weisel Andrew Spencer Robert Orlowski Shibao Feng Karim Iskander Meletios A. Dimopoulos
spellingShingle	Hartmut Goldschmidt Philippe Moreau Heinz Ludwig Ruben Niesvizky Wee Joo Chng Douglas Joshua Katja Weisel Andrew Spencer Robert Orlowski Shibao Feng Karim Iskander Meletios A. Dimopoulos Carfilzomib-Dexamethasone vs Subcutaneous or Intravenous Bortezomib in Relapsed or Refractory Multiple Myeloma: Secondary Analysis of Phase 3 ENDEAVOR Study
author_sort	Hartmut Goldschmidt
title	Carfilzomib-Dexamethasone vs Subcutaneous or Intravenous Bortezomib in Relapsed or Refractory Multiple Myeloma: Secondary Analysis of Phase 3 ENDEAVOR Study
title_short	Carfilzomib-Dexamethasone vs Subcutaneous or Intravenous Bortezomib in Relapsed or Refractory Multiple Myeloma: Secondary Analysis of Phase 3 ENDEAVOR Study
title_full	Carfilzomib-Dexamethasone vs Subcutaneous or Intravenous Bortezomib in Relapsed or Refractory Multiple Myeloma: Secondary Analysis of Phase 3 ENDEAVOR Study
title_fullStr	Carfilzomib-Dexamethasone vs Subcutaneous or Intravenous Bortezomib in Relapsed or Refractory Multiple Myeloma: Secondary Analysis of Phase 3 ENDEAVOR Study
title_full_unstemmed	Carfilzomib-Dexamethasone vs Subcutaneous or Intravenous Bortezomib in Relapsed or Refractory Multiple Myeloma: Secondary Analysis of Phase 3 ENDEAVOR Study
title_sort	carfilzomib-dexamethasone vs subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of phase 3 endeavor study
publisher	Taylor & Francis
publishDate	2018
url	http://scholarbank.nus.edu.sg/handle/10635/143070
_version_	1800913285101387776

Carfilzomib-Dexamethasone vs Subcutaneous or Intravenous Bortezomib in Relapsed or Refractory Multiple Myeloma: Secondary Analysis of Phase 3 ENDEAVOR Study

Similar Items